PHARMACEUTICAL
PM in Manila: Aligning act east, Indo-Pacific & MAHASAGAR policies
Prime Minister Narendra Modi will visit Manila for the ASEAN Summit, focusing on strengthening India's partnerships. The growing competition in the Indo-Pacific requires ASEAN countries to seek reliable collaborations with India. Maritime cooperation, educational exchanges, and renewable energy initiatives are critical areas for future collaboration.
Compulsory licensing of drugs only after exhausting all other measures: Department of Pharmaceuticals secretary Manoj Joshi
The government plans to address the high costs of innovative medicines by first negotiating prices. Compulsory licensing will be considered only after other alternatives are exhausted. Trade margins on high-cost drugs are being examined to enhance affordability. Discussions are ongoing with pharmaceutical companies to improve access and affordability of patented drugs. The government is also working on initiatives to support the local pharmaceutical manufacturing sector.
Blue Jet Healthcare evaluating Rs 500 crore investment in Andhra Pradesh API manufacturing facility
Blue Jet Healthcare is evaluating the acquisition of 50 acres of land in Andhra Pradesh for an API manufacturing facility. The company plans to invest Rs 5 billion in this proposed project. An MoU has been signed with the Andhra Pradesh Economic Development Board for the investment. The land acquisition is currently under evaluation and will enhance the company's manufacturing capabilities in the API segment.
NPPA issues strict guidelines for trade margin rationalisation on 137 cancer drugs to benefit patients
The National Pharmaceutical Pricing Authority has implemented strict monitoring of Trade Margin Rationalisation for certain anti-cancer drugs. Compliance with revised prices has been mandated for manufacturers, retailers, and hospitals. They must display updated price lists to inform patients effectively. Complaints about overcharging or drug shortages can be reported through designated channels. State Drug Controllers have been instructed to submit compliance reports to ensure adherence by 16 November 2026.
PLI schemes achieve 76% of investment target, 64% of production goal: Niti Aayog
The production-linked incentive (PLI) scheme has achieved 76% of its investment target and 64% of its production target, with electronics, telecom and pharmaceuticals emerging as strong performers, Niti Aayog said. As of March 2026, the scheme had attracted ₹2.40 lakh crore in investments, generated production worth ₹22.66 lakh crore and created over 8.49 lakh jobs.
Who is Indian-origin Aarti Shah, who decided Jensen Huang’s fate along with other Nvidia board members?
Jensen Huang has stepped down as the CEO of Nvidia after a long tenure of 33 years. Colette Kress, the chief financial officer, will be acting as the interim CEO during this transition. The board of directors is now involved in the search for Huang's permanent successor. Here's a look at Indian-origin board member Aarti Shah and the other directors involved in the company's leadership transition.
Andhra Pradesh urges Walmart to expand sourcing from MSMEs, women-led SHGs, artisans
Andhra Pradesh's IT and HRD Minister Nara Lokesh met with Walmart's Paul Dyck to discuss local procurement expansion. The state is asking Walmart to source goods from MSMEs, women-led groups, and artisans. Recommendations include hosting an MSME sourcing event focused on seafood and textiles, which would connect local producers to global markets. Dyck acknowledged Walmart's existing purchases from Andhra Pradesh and expressed willingness to consider the state's proposals.
Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment
Lupin Ltd has partnered with Sandoz to launch RanluspecTM, a biosimilar for Ranibizumab, across Europe. This launch will help to improve access to treatments for retinal and choroidal vascular diseases. The European Commission previously approved RanluspecTM in vial and syringe-filled presentations for medical use. The biosimilar targets conditions such as wet age-related macular degeneration and diabetic macular edema.
India may open doors to multinational pharma firms for first-in-human Phase I trials
India is considering modifications to its pharmaceutical regulatory framework to attract multinational companies for clinical trials. Discussions have commenced regarding allowing these companies to conduct Phase I trials in India. Authorities aim to enhance India's appeal for global drug innovation and development. Strengthening manufacturing compliance over the last two years has also been part of the plan.
USFDA classifies Aurobindo Pharma's US facility as 'official action indicated'
The facility belongs to Lannett Company LLC, a wholly owned step-down subsidiary of Aurobindo Pharma. The US Food and Drug Administration (USFDA) conducted the inspection at the Seymour facility from August 17-21, 2026, Aurobindo Pharma said in a regulatory filing.
Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA
Following an inspection from September 7 to September 15, 2026, the US FDA granted Apitoria Pharma, a subsidiary of Aurobindo Pharma, a Voluntary Action Indicated classification. This classification indicates that although objectionable conditions were found in the Telangana manufacturing facility, the absence of immediate regulatory action allows the company to address the issues through voluntary corrective measures.
Drugmakers tap China AI app boom to reach doctors as crackdown upends marketing
As scrutiny intensifies, Chinese pharmaceutical companies are shifting gears toward digital marketing initiatives. Traditional face-to-face communications are waning, prompting the industry to embrace AI-fueled applications for connecting with healthcare providers. These tools facilitate compliant relationships, sparking partnerships among health-tech firms to disseminate clinical information through digital channels. This marks a pivotal change in marketing dynamics within the pharmaceutical landscape.
Government extends ₹2,700-crore PLI scheme for medical devices till 2035-36, eases eligibility norms
The government has extended the ₹2,700-crore production-linked incentive (PLI) scheme for domestic medical device manufacturing until 2035-36 and invited fresh applications with relaxed eligibility and investment conditions. The revised rules remove the minimum sales threshold for claiming incentives and lower the minimum investment requirement to attract more manufacturers.
Cancer drug prices revised from today; patients may save Rs 3,540 crore annually
The government has revised the prices of 1,364 anti-cancer medicine formulations effective from November 9. This decision aims to limit trade margins and reduce consumer costs for cancer drugs. According to official reports, this measure is expected to save consumers Rs 3,540.38 crore each year.
Morepen Laboratories launches Desloratadine (Rx) generic drug product in US market
Morepen Laboratories has launched its prescription generic product Desloratadine in the United States market. This launch is managed through the company's subsidiary, Morpen Bio. Inc. The product will be available in 100-count and 500-count packs to consumers. Additionally, Morepen has submitted an Abbreviated New Drug Application for Sitagliptin Phosphate Tablets to the US FDA. The submission is currently undergoing regulatory review, which is an important step for their expansion.
Pharma industry steps up API investments to cut import dependence, move up value chain
India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.
Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr
Glenmark Pharmaceuticals experienced a 56.78 percent drop in consolidated profit after tax during the September quarter. Total revenue from operations decreased to Rs 4,247.32 crore compared to the previous year. The company's total expenses also decreased during the same period, indicating some operational efficiency. A subsidiary of Glenmark Pharma entered into a settlement for USD 15 million with Humana Inc.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
HRV Pharma buys Germany's Phatebo
The acquisition marks virtual pharmaceutical company HRV's entry beyond active pharmaceutical ingredients (APIs) into finished formulations, giving it its first finished formulations business alongside a licenced operating entity in Germany.
Load More
